| Age, y, mean (SD) |
36.6 (13.3) |
35.3 (13.1) |
38.4 (13.9) |
32.7 (11.3) |
.38 |
| Female |
46 (67) |
10 (63) |
30 (75) |
6 (46) |
.14 |
| Disease duration, y, median (range) |
0.2 (0.0-18.0) |
0.1 (0.0-17.0) |
0.6 (0.0-18.0) |
0.1 (0.0-16.0) |
.07 |
| Disease course |
|
|
|
|
|
| Clinically isolated syndrome |
28 (41) |
8 (50) |
11 (28) |
9 (69) |
.02 |
| Remitting-relapsing |
36 (52) |
7 (44) |
26 (65) |
3 (23) |
.02 |
| Secondary progressive |
5 (7) |
1 (6) |
3 (8) |
1 (8) |
>.99 |
| Expanded Disability Status Scale score |
|
|
|
|
|
| Score at baseline, median (range) |
1.0 (0.0-8.5) |
0.0 (0.0-6.5) |
2.0 (0.0-8.5) |
0.0 (0.0-8.5) |
.20 |
| Score at index attack, median (range) |
6.0 (2.0-9.5) |
7.5 (3.5-9.5) |
5.0 (2.0-9.5) |
6.0 (3.0-9.0) |
.12 |
| Immunoadsorption and plasma exchange treatment |
|
|
|
|
|
| Initiation delay, d, mean (SD) |
25.4 (20.4) |
16.3 (13.6) |
26.5 (22.8) |
33.2 (16.1) |
.07 |
| Therapy with high-dose corticosteroids before initiation |
63 (91) |
13 (81) |
37 (93) |
13 (100) |
.19 |
| Therapy with disease-modifying drugs in the 3 mo before initiation, No./Total No. (%) |
17/67 (25) |
5/15 (33) |
11/39 (28) |
1 (8) |
.25 |
